Multiple world-leading pharmaceutical companies and venture capital investors are actively seeking in vivo cell and gene therapy (CGT) platforms and therapeutic candidates for thalassemia and sickle cell anemia.
There is substantial and urgent demand for relevant assets.
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
